Recursion Pharmaceuticals

Recursion Pharmaceuticals! WTH is going on?

537578

Not Invested

Community Contributor

Published

14 Feb 26

Updated

03 May 26

Views

869

03 May

US$3.59

537578's Fair Value

US$1.97

82.2% overvalued

-14.1%

19.3%

-14.1%

19.3%

You can edit this narrative until May 4 5:35 PM. Then, changes will post as Updates.

Author's Valuation

US$1.9782.2% overvalued

537578's Fair Value

Shared on 03 May 26

Recursion Pharmaceuticals (RXRX) one day will be the Palantir of biotechnology! With the CMO transitioning out as well as the former CEO RXRX now has a chance to take off!

65 views

Shared on 11 Apr 26

I was very pessimistic about RXRX! I am now extremely optimistic and here’s why!

111 views

Shared on 02 Mar 26

As I see what RXRX did in the 4th quarter I now believe they will be the Palantir of biotechnology one day! Najat Khan the new CEO will lead this company out of the hole created by the former CEO into greatness!

130 views

Valuator

Company Info

Notes

537578'sFair Value

US$1.97

82.2% overvalued

Future estimation in

Revenue

Profit Margin

Future PE

Est. Revenue

Forecast revenue growth rate

31.30%

Historical revenue growth rate

31.89%

Biotech revenue growth rate

11.41%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

Decrease

Increase

Current discount rate

7.20%

Calculation

US$71.18m

Earnings '31

28.47x

PE Ratio '31

US$2.03b

Market Cap '31

US$2.03b

Market Cap '31

731.10m

No. shares '31

US$2.77

Share Price '31

US$2.77 Share Price '31

Discounted to 2026 @ 7.13% p.a.

US$1.97

Fair Value '26